Abstract
Spinal muscular atrophy (SMA) is a progressive disease involving the degeneration of motor neurons with no currently available treatment. While valproic acid (VPA) is a potential treatment for SMA, its therapeutic mechanisms are still controversial. In this study, we investigated the mechanisms of action of VPA in the treatment of type III-like SMA mice. SMA and wild-type mice were treated with VPA from 6 to 12 months and 10 to 12 months of age, respectively. Untreated SMA littermates and age-matched wild-type mice were used for comparison. VPA-treated SMA mice showed better motor function, larger motor-evoked potentials, less degeneration of spinal motor neurons, less muscle atrophy, and better neuromuscular junction innervation than non-treated SMA mice. VPA elevated SMN protein levels in the spinal cord through SMN2 promoter activation and probable restoration of correct splicing of SMN2 pre-messenger RNA. VPA also increased levels of anti-apoptotic factors, Bcl-2 and Bcl-xL, in spinal neurons. VPA probably induced neurogenesis and promoted astrocyte proliferation in the spinal cord of type III-like SMA mice, which might contribute to therapeutic effects by enhancing neuroprotection. Through these effects of elevation of SMN protein level, anti-apoptosis, and probable neuroprotection, VPA-treated SMA mice had less degeneration of spinal motor neurons and better motor function than untreated type III-like SMA mice.
Similar content being viewed by others
Abbreviations
- ALS:
-
amyotrophic lateral sclerosis
- ATPase:
-
adenosine triphosphatase
- BrdU:
-
bromodeoxyuridine
- ChAT:
-
choline acetyltransferase
- CMAP:
-
compound muscle action potential
- GFAP:
-
glial fibrillary acidic protein
- HDAC:
-
histone deacetylase
- NeuN:
-
neuronal nuclear
- SMA:
-
spinal muscular atrophy
- SMN:
-
survival motor neuron
- VPA:
-
valproic acid
- vWF:
-
von Willebrand factor
References
Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 13:155–165
Wirth B (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 15:228–237
Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12:2481–2489
Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, Schussler K, Chen X, Jarecki J, Burghes AH, Taylor JP, Fischbeck KH (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54:647–654
Tsai LK, Tsai MS, Lin TB, Hwu, WL, Li H (2006) Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 24:286–295
Brichta L, Holker I, Haug K, Klockgether T, Wirth B (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 59:970–975
Tsai LK, Yang CC, Hwu WL, Li H (2007) Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol 14:e8–9
Weihl CC, Connolly AM, Pestronk A (2006) Valproate may improve strength and function in patients with type III/IV spinal muscular atrophy. Neurology 67:500–501
National Institutes of Health, US (2006) Valproic acid and carnitine in patients with spinal muscular atrophy. http://www.clinicaltrials.gov/ct/gui/show/NCT00227266. Accessed 29 Jan 2007
Bergeijk JV, Haastert K, Grothe C, Claus P (2006) Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein. Chem Biol Drug Des 67:244–247
Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein Bcl-2 in the CNS. J Neurochem 72:879–882
Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311–7316
Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, Chen G (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 24:6590–6599
Avila AM, Burnett BG, Taye AA, Gabanella F et al (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117:659–671
Iezzi S, Padova MD, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V (2004) Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 6:673–684
Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H (2000) A mouse model for spinal muscular atrophy. Nat Genet 24:66–70
Tsai LK, Tai MS, Ting CH, Wang SH, Li H (2008) Restoring Bcl-xL levels benefits a mouse model of spinal muscular atrophy. Neurobiol Dis. doi:10.1016/j.nbd.2008.05.014
Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind? Arch Neurol 23:369–379
Ting CH, Lin CW, Wen SL, Hsieh-Li HM, Li H (2007) Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum Mol Genet 16:499–514
Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, Finkel RS, Dreyfuss G, Fischbeck KH (2006) SMN mRNA and protein levels in peripheral blood, biomarkers for SMA clinical trials. Neurology 66:1067–1073
Shyu WC, Lin SZ, Yang HI, Tzeng YS, Pang CY, Yen PS, Li H (2004) Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells. Circulation 110:1847–1854
Cifuentes-Diaz C, Nicole S, Velasco ME, Borra-Cebrian C, Panozzo C, Frugier T, Millet G, Roblot N, Joshi V, Melki J (2002) Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet 11:1439–1447
Gubitz AK, Feng W, Dreyfuss G (2004) The SMN complex. Exp Cell Res 296:51–56
Rajendra TK, Gonsalvez GB, Walker MP, Shpargel KB, Salz HK, Matera AG (2007) A Drosophila melanogaster model of spinal muscular atrophy reveals a function for SMN in striated muscle. J Cell Biol 176:831–841
Cifuentes-Diaz C, Frugier T, Tiziano FD, Lacene E, Roblot N, Joshi V, Moreau MH, Melki J (2001) Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol 152:1107–1114
Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, Boucheron C, Mollat P, Gisselbrecht S, Gouilleux F (1999) IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18:4191–4199
Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AH, Prior TW (1998) Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. Am J Hum Genet 63:1712–1723
Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358–368
Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont, O, Munnich A, Dreyfuss G, Melki J (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16:265–269
Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, Coulson SE, Androphy EJ, Prior TW, Burghes AH (1997) The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6:1205–1214
Soler-Botija C, Ferrer I, Alvarez JL, Baiget M, Tizzano EF (2003) Downregulation of Bcl-2 proteins in type I spinal muscular atrophy motor neurons during fetal development. J Neuropathol Exp Neurol 62:420–426
Araki S, Hayashi M, Tamagawa K, Saito M, Kato S, Komori T, Sakakihara Y, Mizutani T, Oda M (2003) Neuropathological analysis in spinal muscular atrophy type II. Acta Neurophathol 106:441–448
Johansson CB, Momma S, Clarke DR, Risling M, Lendahl U, Frisen J (1999) Identification of a neural stem cell in the adult mammalian central nervous system. Cell 96:25–34
Martens DJ, Seaberg RM, van der Kooy D (2002) In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neuronal progenitors around the fourth ventricle and the central canal of the spinal cord. Eur J Neurosci 16:1045–1057
Mothe AJ, Tator CH (2005) Proliferation, migration, and differentiation of endogenous ependymal region stem/progenitor cells following minimal spinal cord injury in the adult rat. Neuroscience 131:177–187
Zai LJ, Wrathall JR (2005) Cell proliferation and replacement following contusive spinal cord injury. Glia 50:247–257
De Hemptinne I, Boucherie C, Pochet R, Bantubungi K, Schiffmann SN, Maloteaux JM, Hermans E (2006) Unilateral induction of progenitors in the spinal cord of hSOD1G93A transgenic rats correlates with an asymmetrical hind limb paralysis. Neurosci Lett 401:25–29
Ohta Y, Nagai M, Nagata T, Murakami T, Nagano I, Narai H, Kurata T, Shiote M, Shoji M, Abe K (2006) Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene. J Neurosci Res 84:980–992
Ke Y, Chi L, Xu R, Luo C, Gozal D, Liu R (2006) Early response of endogenous adult neural progenitor cells to acute spinal cord injury in mice. Stem cell 24:1011–1019
Talbot K, Davies KE (2001) Spinal muscular atrophy. Semin Neurol 21:189–196
Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Eng J Med 344:1688–1700
Brodie MJ, Dichter MA (1996) Antiepileptic drugs. New Engl J Med 334:168–175
Acknowledgments
This work was supported in part by the National Health Research Institute (grant NHRI-EX92-9029sp), National Taiwan University Hospital (grant NTUH-96M04), and Department of Medical Research of National Taiwan University Hospital. The authors thank Dr. Tzer-Bin Lin for electrophysiological equipment support.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
Immunohistological analysis of the spinal anterior horn in untreated SMA (S–, a–c, n = 4), VPA-treated SMA (S+, d–f, n = 4), untreated wild-type (W−, g–i, n = 4) and VPA-treated wild-type mice (W+, n = 4). Spinal cord sections were stained for choline acetyltransferase (ChAT, red) and SMN (green) and for nuclei using DAPI (blue). ChAT-immunopositive cells are divided into three categories, including cells without SMN immunoreactivity (SMN(−), empty arrow), with partial SMN immunoreactivity (SMN(+/−), white arrow), and with full SMN immunoreactivity (SMN(+)). j VPA-treated SMN mice showed higher percentage of SMN(+) cells and lower percentage of SMN(−) cells than untreated SMA mice. k Higher gem (arrowhead) numbers in the nuclei could be detected in spinal neurons of VPA-treated SMA mice in comparison with untreated SMA mice. Scale bars 50 μm; *P < 0.05; **P ≤ 0.01 (GIF 550 kb)
Supplementary Fig. 2
Immunohistological analysis of the muscles in a negative control (not adding SMN antibody), b untreated SMA, c valproic acid (VPA)-treated SMA, and d untreated wild-type mice. Muscle sections were stained for SMN (green) and for nuclei using DAPI (blue). There was more SMN signal in muscles of VPA-treated than non-treated SMA mice. Scale bars 50 μm (GIF 1189 kb)
Supplementary Fig. 3
Histological analysis of the spinal anterior horn in untreated SMA (S−, a, d, n = 4), VPA-treated SMA (S+, b, e, n = 4), untreated wild-type (W−, c, f, n = 4) and VPA-treated wild-type mice (W+, n = 4). Spinal cord sections were stained for Bcl-2 (a–c, red) or Bcl-xL (d–f, red) with NeuN (green) and for nuclei using DAPI (blue). NeuN/Bcl-2 or NeuN/Bcl-xL double-labeled cells appeared to be yellow, while NeuN-immunopositive but Bcl-2 or Bcl-xL-immunonegative cells displayed green color. g VPA-treated SMA mice showed a higher percentage of NeuN-immunopositive cells displaying Bcl-2 immunopositive signal in the spinal cord as compared with untreated SMA mice. h VPA-treated SMA mice had a higher percentage of NeuN immunopositive cells displaying Bcl-xL-immunopositive signal in the spinal cord than untreated SMA mice. Scale bars 50 μm; *P < 0.05; **P ≤ 0.01 (GIF 547 kb)
Supplementary Fig. 4
Blots of the indicated figures for reactivity of antibodies used in our manuscript. For experimental design, see legends of the indicated figures and the “Materials and methods” section (GIF 374 kb)
Rights and permissions
About this article
Cite this article
Tsai, LK., Tsai, MS., Ting, CH. et al. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 86, 1243–1254 (2008). https://doi.org/10.1007/s00109-008-0388-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-008-0388-1